Wexford Capital’s ProKidney PROK Stock Holding History

Wexford Capital’s Portfolio PROK Stock Details PROK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-12,580	Closed	-$22.4K	–	269
2023 Q4	$22.4K	Buy	+12,580	New	+$27K	﹤0.01%	186

Other funds holding PROK

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Brown University Providence, Rhode Island $102M AUM 26.79% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wexford Capital's PROK Position: Q1 2024 in Review

Wexford Capital sold out of ProKidney (PROK) in Q1 2024, closing a stake of 12,580 shares — an estimated $22.4K sold.

Wexford Capital first reported a position in PROK in Q4 2023 and held it in 1 quarter. The position peaked at $22.4K in Q4 2023. 55 funds tracked by Wall St. Rank hold PROK as of Q1 2024.

Wexford Capital reported no remaining ProKidney position as of Q1 2024 after selling out during the quarter.
Wexford Capital sold 12,580 ProKidney shares in Q1 2024, an estimated $22.4K.
Wexford Capital first reported a position in ProKidney in Q4 2023 and held it in 1 quarter.
Wexford Capital's ProKidney position peaked at $22.4K in Q4 2023.
55 funds tracked by Wall St. Rank held ProKidney as of Q1 2024.

Based on Wexford Capital's 13F filing for Q1 2024, filed 15 May 2024.